Skip to main content
Dryad

Data and code from: Acetic acid chromoendoscopy for the detection of neoplastic Barrett esophagus: a stepped wedge cluster randomized controlled trial (ACID-trial)

Data files

Jun 23, 2026 version files 771.59 KB

Click names to download individual files

Abstract

Acetic acid chromoendoscopy (AAC) is believed to be useful as a ‘red flag’ technique in Barrett esophagus (BE) surveillance, thereby improving the detection of dysplasia and esophageal adenocarcinoma (EAC). We assessed the added value of AAC in routine clinical practice. A total of 18 Dutch community hospitals participated in this stepped wedge cluster, randomized trial. Patients undergoing BE surveillance were eligible, excluding those with known or previously treated dysplasia. Hospitals randomly shifted from surveillance without AAC (control) to AAC (intervention) Targeted biopsies were obtained if lesions were present, before conducting random four-quadrant biopsies. Primary endpoint was the neoplasia detection rate, defined as the percentage of patients with low-grade dysplasia (LGD), high-grade dysplasia (HGD) and EAC in any biopsy. Secondary endpoints included neoplasia detection rate stratified by degree of dysplasia, neoplasia detection rate in targeted biopsies, and procedure time. We found that AAC-use did not increase the neoplasia detection rate. This also applied for the detection rate of LGD, and for HGD and EAC combined. More suspected lesions were detected in patients receiving AAC, yet the targeted neoplasia detection rate was not higher compared to patients in the control group. The total procedure time was longer during BE surveillance endoscopies when AAC was used. In addition, the increase of total procedure time was larger at the start of the AAC-guided surveillance compared to the AAC-guided endoscopies performed at the end of the trial. In a community hospital setting, characterized by procedures performed by non-expert BE endoscopists and a patient population at relatively low risk of EAC, AAC did not demonstrate added value.